Legend Biotech (NASDAQ:LEGN) (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.
The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma. Carvykti received U.S. Food and Drug Administration approval in February 2022, marking Legend Biotech’s transition into commercial operations. Beyond its flagship program, the company maintains a diversified pipeline, which includes additional hematologic and solid-tumor cell therapy candidates and next-generation platform technologies designed to enhance safety, scalability and patient access.
Founded in 2014 and backed by a robust collaboration agreement with Janssen, Legend Biotech completed its initial public offering on the Nasdaq in July 2019. The capital raise supported expansion of manufacturing capacity and accelerated global clinical development. Through its relationship with Janssen, Legend Biotech has laid the groundwork for regulatory filings and product launches across North America, Europe and Asia, leveraging Janssen’s established commercial network.
The company is led by Chief Executive Officer Dr. Ying Huang, whose leadership team combines expertise in cell therapy research, regulatory affairs and commercial execution. As Legend Biotech advances its clinical programs and scales its commercial infrastructure, it remains focused on expanding patient access to transformative therapies and exploring new indications in oncology.
